title: Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes.
abstract: OBJECTIVE
  To assess the efficacy of OnabotulinumtoxinA (BTXA) injections in men with drug-refractory non-neurogenic overactive bladder (NNOAB).
  
  
  METHODS
  A total of 43 men received BTXA injections for NNOAB from 2004 to 2012. Patient Global Impression of Improvement (PGI-I) score was obtained. For men with wet NNOAB, change in number of pads per day was also assessed.
  
  
  RESULTS
  Forty-three men with a mean age of 69 (range 37-85) received at least one injection. Of the 43 men, 20 (47%) had prior prostate surgery: 11 had radical prostatectomy (RP) and nine had transurethral resection of prostate (TURP). Overall, average PGI-I score was 2.7. Comparing PGI-I score in men who had prior prostate surgery with men who have not: 2.6 ± 0.5 vs 2.8 ± 0.5 respectively (average ± 95% CI), P = 0.6. Comparing PGI-I score in men who had previous TURP with men who had previous RP: PGI-I score: 3.3 ± 0.8 vs 2.0 ± 0.5 respectively, P < 0.05. Men who had RP experienced a reduction in pad use (from 3.5 ± 1.7 to 1.6 ± 0.9 pads/day, P < 0.05) while this was not the case amongst men who had TURP (from 1.7 ± 1.5 to 1.4 ± 1.5 pads/day, P = 0.4).
  
  
  CONCLUSIONS
  Overall, BTXA injection in men with drug-refractory NNOAB does provide a symptomatic benefit. Amongst men who have had prior prostate surgery, men who have had RP experience a greater benefit than men who have had TURP, both in regards to PGI-I score and pad use.
authors.affiliation: Concord Repatriation General Hospital, Sydney, NSW, Australia.
authors.forename: David
authors.initials: D
authors.lastname: Habashy
authors.affiliation: Concord Repatriation General Hospital, Sydney, NSW, Australia.
authors.forename: Giovanni
authors.identifier: http://orcid.org/0000-0003-2939-1650
authors.initials: G
authors.lastname: Losco
authors.affiliation: Concord Repatriation General Hospital, Sydney, NSW, Australia.|University of Sydney, Sydney, NSW, Australia.
authors.forename: Vincent
authors.initials: V
authors.lastname: Tse
authors.affiliation: Concord Repatriation General Hospital, Sydney, NSW, Australia.
authors.forename: Ruth
authors.initials: R
authors.lastname: Collins
authors.affiliation: Concord Repatriation General Hospital, Sydney, NSW, Australia.|University of Sydney, Sydney, NSW, Australia.
authors.forename: Lewis
authors.initials: L
authors.lastname: Chan
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011788:Quality of Life / Q000523:psychology; D012189:Retrospective Studies; D020728:Transurethral Resection of Prostate; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000523:psychology; D014549:Urinary Incontinence / Q000188:drug therapy*
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A
keywords: Botulinum toxins, type A; lower urinary tract symptoms; prostatic neoplasms; urinary bladder, overactive; urinary incontinence, stress